99 related articles for article (PubMed ID: 16303613)
1. Transforming growth factor beta1 and prostaglandin E2 concentrations are associated with bone formation markers in ulcerative colitis patients.
Wiercinska-Drapalo A; Jaroszewicz J; Tarasow E; Flisiak R; Prokopowicz D
Prostaglandins Other Lipid Mediat; 2005 Dec; 78(1-4):160-8. PubMed ID: 16303613
[TBL] [Abstract][Full Text] [Related]
2. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin, IL-6, IL-1, TNF-alpha and TGF-beta concentrations during acetate-free biofiltration.
Buemi M; Floccari F; Crisafulli A; Cavallaro E; Ruello A; Caccamo C; Loddo S; Aloisi C; Corica F; Romeo A; Frisina N; Teti D
J Nephrol; 2005; 18(2):148-53. PubMed ID: 15931642
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
5. Effect of ulcerative colitis activity on plasma concentration of transforming growth factor beta1.
Wiercińska-Drapało A; Flisiak R; Prokopowicz D
Cytokine; 2001 Jun; 14(6):343-6. PubMed ID: 11497495
[TBL] [Abstract][Full Text] [Related]
6. Circulating transforming growth factor beta1 (TGFbeta1) is elevated by extensive exercise.
Hering S; Jost C; Schulz H; Hellmich B; Schatz H; Pfeiffer H
Eur J Appl Physiol; 2002 Mar; 86(5):406-10. PubMed ID: 11882926
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta1 and its receptors in patients with ulcerative colitis.
Stadnicki A; Machnik G; Klimacka-Nawrot E; Wolanska-Karut A; Labuzek K
Int Immunopharmacol; 2009 Jun; 9(6):761-6. PubMed ID: 19285572
[TBL] [Abstract][Full Text] [Related]
8. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
9. [Expression with TGFbeta1 in the patients with ulcerative colitis].
Wang YF; Wei B; Ouyang Q
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):204-6. PubMed ID: 15807267
[TBL] [Abstract][Full Text] [Related]
10. Plasma and mucosal prostaglandin E2 as a surrogate marker of ulcerative colitis activity.
Wiercińska-Drapało A; Flisiak R; Prokopowicz D
Rocz Akad Med Bialymst; 2001; 46():60-8. PubMed ID: 11780581
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.
Magal I; Lebel E; Altarescu G; Itzchaki M; Rudensky B; Foldes AJ; Zimran A; Elstein D
Br J Haematol; 2006 Apr; 133(1):93-7. PubMed ID: 16512834
[TBL] [Abstract][Full Text] [Related]
12. Mucosal synthesis and release of prostaglandin E2 from activated eosinophils and macrophages in ulcerative colitis.
Raab Y; Sundberg C; Hällgren R; Knutson L; Gerdin B
Am J Gastroenterol; 1995 Apr; 90(4):614-20. PubMed ID: 7717321
[TBL] [Abstract][Full Text] [Related]
13. Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis.
Hofbauer LC; Schoppet M; Christ M; Teichmann J; Lange U
Rheumatology (Oxford); 2006 Oct; 45(10):1218-22. PubMed ID: 16574701
[TBL] [Abstract][Full Text] [Related]
14. Mucosal and plasma prostaglandin E2 in ulcerative colitis.
Wiercinska-Drapalo A; Flisiak R; Prokopowicz D
Hepatogastroenterology; 1999; 46(28):2338-42. PubMed ID: 10521993
[TBL] [Abstract][Full Text] [Related]
15. Are activated T cells regulators of bone metabolism in children with Crohn disease?
Sylvester FA; Davis PM; Wyzga N; Hyams JS; Lerer T
J Pediatr; 2006 Apr; 148(4):461-6. PubMed ID: 16647405
[TBL] [Abstract][Full Text] [Related]
16. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
17. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
18. The effect of acute psychologic stress on systemic and rectal mucosal measures of inflammation in ulcerative colitis.
Mawdsley JE; Macey MG; Feakins RM; Langmead L; Rampton DS
Gastroenterology; 2006 Aug; 131(2):410-9. PubMed ID: 16890594
[TBL] [Abstract][Full Text] [Related]
19. Study on the correlations among disease activity index and salivary transforming growth factor-beta 1 and nitric oxide in ulcerative colitis patients.
Rezaie A; Khalaj S; Shabihkhani M; Nikfar S; Zamani MJ; Mohammadirad A; Daryani NE; Abdollahi M
Ann N Y Acad Sci; 2007 Jan; 1095():305-14. PubMed ID: 17404043
[TBL] [Abstract][Full Text] [Related]
20. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept.
Woo JH; Lee HJ; Sung IH; Kim TH
J Rheumatol; 2007 Aug; 34(8):1753-9. PubMed ID: 17610317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]